| Autor: |
Isabel H. Gonzalez-Bocco, Katherine Beluch, Alyssa Cho, Chloe Lahoud, Fabiola A. Reyes, Dimitrios G. Moshovitis, Gillian M. Unger-Mochrie, Wei Wang, Sarah P. Hammond, Jennifer Manne-Goehler, Sophia Koo |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Pilot and Feasibility Studies, Vol 9, Iss 1, Pp 1-10 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2055-5784 |
| DOI: |
10.1186/s40814-023-01325-y |
| Popis: |
Abstract Background Multiple vaccines have been approved since August 2021 to prevent infection with SARS-CoV-2; however, 20–40% of immunocompromised people fail to develop SARS-CoV-2 spike antibodies after COVID-19 vaccination and remain at high risk of infection and more severe illness than non-immunocompromised hosts. Sotrovimab (VIR-7831) is a monoclonal neutralizing antibody that binds a conserved epitope on the SARS-CoV-2 spike protein. It is neither renally excreted nor metabolized by P450 enzymes and therefore unlikely to interact with concomitant medications (e.g., immunosuppressive medications). In this open-label feasibility study protocol, we will define the optimal dose and dosing interval of sotrovimab as pre-exposure prophylaxis for immunocompromised individuals as well as its safety and tolerability in this population specifically. Methods We will enroll 93 eligible immunocompromised adults with a negative or low-positive ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
